PT Staff

An organ transplant is a known risk factor for C. difficile infection, however, data are lacking on how the infection affects those who underwent an intestinal transplant.

Zilucoplan is among highlighted products of the month.

Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that inhibits cytokine signaling in psoriasis pathogenesis.

Research shows that some unsuccessful switches from reference products to biosimilars may be attributed to patient perceptions of reduced efficacy and safety.

Molecular methods such as polymerase chain reaction show promise in monitoring the patient environment in hospitals and could help to provide reassurance prior to admission.

Products range from natural eye relief to sleep aid.

YLB113 (Nepexto) produced significantly lower injection site reactions and injection site erythema compared with etanercept in patients with rheumatoid arthritis.

Patients with cystic fibrosis are typically administered antibiotics throughout their lives, which can increase the risk for C difficile infections.

Approximately half of patients with heart failure do not require an implantable monitoring device or do not qualify for thoracic monitoring.

There have been more than 80,000 monkeypox cases reported worldwide.

Greater prevalence of hand eczema among health care professionals working in COVID-19 units linked to increased hand sanitation habits.

Study finds a strong decline in hepatitis C incidence in the years immediately following broad access to direct-acting antiviral drugs.

Clinical trials show that patients with atopic dermatitis experienced improved symptoms with dupilumab starting at 8 weeks, with maximum effect around 12 weeks.

Products include a vaccine for meningococcal disease and a new type of COVID-19 test.

Products range from acne treatment to cough relief.

Cariprazine (Vraylar; AbbVie, Gedeon Richter) is indicated as an adjunctive therapy to antidepressants for treating adult patients with major depressive disorder.

Adalimumab-aacf (Idacio) is indicated for chronic conditions such as rheumatoid arthritis, plaque psoriasis, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and juvenile idiopathic arthritis.

Study finds gluten-free diets may play an important role in the causality of celiac disease on the development of psoriasis.

Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.

Regular physical activity helps to facilitate a healthy gut microbiome and lowers inflammation, which were observed in patients independent of body mass index.

Prior research indicates a platelet-based connection between migraine and the patent foramen ovale.

Herpes zoster and postherpetic neuralgia can cause a significant health burden among adults 65 years of age and older.

Dapagliflozin (Farxiga) found effective in lowering the risk of hospitalization for patients with chronic kidney disease, with or without a diagnosis of type 2 diabetes, and increased the number of days alive and out of the hospital.

Lead compounds may lower the risk of abuse and other adverse effects compared with other drugs currently being evaluated for mental health disorders, such as MDMA.

Study findings may make durvalumab plus chemotherapy a new standard of care option for patients with advanced biliary tract cancer.

Palivizumab is a humanized monoclonal antibody approved by the FDA to prevent serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children.

The presence of CD8+ cells may help predict outcomes for patients administered immune checkpoint inhibitors.

Zavegepant could become the first intranasal drug that targets CGRP in migraine sufferers to gain FDA approval.

Atrasentan has been found to lower albuminuria, which correlates with reductions in low-density lipoprotein cholesterol and triglycerides.